0IFK Stock Overview
A clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Editas Medicine, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.20 |
| 52 Week High | US$11.57 |
| 52 Week Low | US$1.20 |
| Beta | 1.87 |
| 1 Month Change | -50.22% |
| 3 Month Change | -65.31% |
| 1 Year Change | -88.34% |
| 3 Year Change | -95.54% |
| 5 Year Change | -96.24% |
| Change since IPO | -96.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0IFK | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -17.8% | -1.0% | -0.6% |
| 1Y | -88.3% | -24.1% | 3.1% |
Return vs Industry: 0IFK underperformed the UK Biotechs industry which returned -24.1% over the past year.
Return vs Market: 0IFK underperformed the UK Market which returned 3.1% over the past year.
Price Volatility
| 0IFK volatility | |
|---|---|
| 0IFK Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0IFK's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0IFK's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 265 | Gilmore O’Neill | www.editasmedicine.com |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
Editas Medicine, Inc. Fundamentals Summary
| 0IFK fundamental statistics | |
|---|---|
| Market cap | US$99.88m |
| Earnings (TTM) | -US$210.57m |
| Revenue (TTM) | US$61.76m |
1.6x
P/S Ratio-0.5x
P/E RatioIs 0IFK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0IFK income statement (TTM) | |
|---|---|
| Revenue | US$61.76m |
| Cost of Revenue | US$220.19m |
| Gross Profit | -US$158.43m |
| Other Expenses | US$52.14m |
| Earnings | -US$210.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.55 |
| Gross Margin | -256.53% |
| Net Profit Margin | -340.96% |
| Debt/Equity Ratio | 0% |
How did 0IFK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 20:35 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Editas Medicine, Inc. is covered by 34 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Joel Beatty | Baird |
| Huidong Wang | Barclays |